NKG2D defines tumor-reacting effector CD8+ T cells within tumor microenvironment

Marija Mojic, Kiyomi Shitaoka, Chikako Ohshima, Sisca Ucche, Fulian Lyu, Hiroshi Hamana, Hideaki Tahara, Hiroyuki Kishi, Yoshihiro Hayakawa*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

For successful immunotherapy for cancer, it is important to understand the immunological status of tumor antigen-specific CD8+ T cells in the tumor microenvironment during tumor progression. In this study, we monitored the behavior of B16OVA-Luc cells in mice immunized with a model tumor antigen ovalbumin (OVA). Using bioluminescence imaging, we identified the time series of OVA-specific CD8+ T-cell responses during tumor progression: initial progression, immune control, and the escape phase. As a result of analyzing the status of tumor antigen-specific CD8+ cells in those 3 different phases, we found that the expression of NKG2D defines tumor-reacting effector CD8+ T cells. NKG2D may control the fate and TOX expression of tumor-reacting CD8+ T cells, considering that NKG2D blockade in OVA-vaccinated mice delayed the growth of the B16OVA-Luc2 tumor and increased the presence of tumor-infiltrating OVA-specific CD8+ T cells.

Original languageEnglish
Pages (from-to)3484-3490
Number of pages7
JournalCancer Science
Volume112
Issue number9
DOIs
StatePublished - 2021/09

Keywords

  • NKG2D
  • TOX
  • cytotoxic T cell
  • immune surveillance
  • tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'NKG2D defines tumor-reacting effector CD8+ T cells within tumor microenvironment'. Together they form a unique fingerprint.

Cite this